Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This prospective study found that tibolone significantly increased the risk of endometrial polyps threefold compared to continuous-combined hormone therapy in postmenopausal women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group. DESIGN: A total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study. RESULTS: Two hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps. CONCLUSIONS: Tibolone increases by threefold the risk for endometrial polyps.
Full text
1,330 characters
· extracted from
oa-doi-fallback
· 3 sections
· click to expand
Objective
To assess the incidence of endometrial polyps during postmenopausal replacement therapy with tibolone, using an appropriate control group.
Design
A total of 485 postmenopausal women were included in this open, prospective, comparative study for a duration of 36 months. Of this group, 249 women received 2.5 mg/day of tibolone and 244 women served as controls, receiving continuous-combined estrogen-progestogen therapy (HT). Transvaginal ultrasound, hysteroscopy, and directed biopsies were performed before treatment was initiated and at the end of the study.
Results
Two hundred twenty-one of the women receiving tibolone and 203 receiving continuous-combined HT completed the study. Endometrial polyps were detected in 74 women (33.4%) from the tibolone group and in 22 women (10.8%) from the HT group (P < 0.01). The vaginal bleeding rate did not differ between the groups. The frequency of atrophic polyps was significantly higher in the tibolone group (P < 0.01). No difference was found in the size of the polyps.
Conclusions
Tibolone increases by threefold the risk for endometrial polyps.
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Org OD 14 and the endometrium 1991
- Long term effects of tibolone on the genital tract in postmenopausal women 1999
- Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem®) a comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound 1997
Cited by (3)
- A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness 2005
- The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with tibolone add-back therapy in endometriosis patients of reproductive age 2006
- Cyclooxygenase-2 expression in endometrial polyps during menopause 2005
References (11)
- Endometrial status in post-menopausal women on long-term continuous combined hormone replacement therapy (Kliofem®) a comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound via openalex
- Long term effects of tibolone on the genital tract in postmenopausal women via openalex
- Org OD 14 and the endometrium via openalex
- doi:10.1016/0022-4731(90)90196-y via openalex
- doi:10.1016/0378-5122(96)01206-6 via openalex
- doi:10.1136/bmj.325.7358.239 via openalex
- doi:10.1046/j.1469-0705.2000.00091.x via openalex
- doi:10.1016/0378-5122(80)90028-6 via openalex
- doi:10.1016/0029-7844(95)00172-n via openalex
- doi:10.1111/j.1471-0528.2002.01338.x via openalex
- doi:10.1016/0378-5122(94)00868-8 via openalex
Cited by (3)
- The incidence and characteristics of uterine bleeding during postoperative GnRH agonist treatment combined with tibolone add-back therapy in endometriosis patients of reproductive age 2006
- Cyclooxygenase-2 expression in endometrial polyps during menopause 2005
- A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness 2005
Source provenance
- openalex
- last seen: 2026-05-11T06:17:40.080092+00:00
License: CC0
· commercial use OK